U.S. Markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.66+0.20 (+8.13%)
At close: 4:00PM EDT
People also watch
ACADARRYCLVSSRPTSGEN
  • H
    Hokiefun
    Hokiefun
    Looks like two abstracts from SITC coming up in November. I could have missed a few.
    Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Lawrence Thomas1, Laura Vitale2, Thomas O'Neill2, Jenifer Widger2, Andrea Crocker2, Li-Zhen He2, Jeffrey Weidlick2, Karuna Sundarapandiyan2, James Storey1, Eric Forsberg1, Catherine Pilsmaker1, Lauren Gergel1, Elizabeth Do1, Joel Goldstein2, Henry Marsh1, Tibor Keler2
    1Celldex Therapeutics, Needham, MA, USA 2Celldex Therapeutics, Hampton, NJ, USA
  • M
    Michael M
    Michael M
    I am new here, just established my first position. Hope I made a wise decision. Cheers!
  • H
    Hokiefun
    Hokiefun
    Glembatumumab Vedotin (GV), an Anti-gpNMB Antibody-Drug Conjugate (ADC), in Combination with Varlilumab (V), an Anti-CD27 Antibody, in Advanced Melanoma
    Omid Hamid1, Anna C. Pavlick2, C. Lance Cowey3, Lowell Hart4, Douglas B. Johnson5, Jose Lutzky6, Aaron Alizadeh7, David Spigel8, Neal Rothschild9, April Salama10, Robert Weber11, Jason J. Luke12, Ying Wang13, Michael Yellin13, Yi He13, Rebecca G. Bagley13, Patrick Ott14
    1The Angeles Clinic and Research Institute, Los Angeles, CA, USA 2New York University School of Medicine, New York, NY, USA 3Baylor University Medical Center, Dallas, TX, USA 4Florida Cancer Specialists, Fort Myers, FL, USA 5Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA 6Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA 7Northside Hospital, Atlanta, GA, USA 8Tennessee Oncology, PLLC, Nashville, TN, USA 9Florida Cancer Specialists, West Palm Beach, FL, USA 10Duke University, Durham, NC, USA 11St. Mary's Medical Center, San Francisco, CA, USA 12University of Chicago, Chicago, IL, USA 13Celldex Therapeutics, Inc., Hampton, NJ, USA 14Dana-Farber Cancer Institute, Boston, MA, USA
  • s
    smart guy
    smart guy
    more proof that mark should have closed out his short and gone long at least short term. These runs to the 2.70's and 2.60's have been profitable. So instead of benefiting he's had dead to losing money on his short for quite a while now. Bad investing.
  • R
    Richard
    Richard
    So....now there are two of us Richards? I'm the one holding the 171 lb. yellowfin tuna.
  • J
    JAM
    JAM
    Patience is a virtue.
  • J
    John
    John
    Goldman has a strangle hold on this stock. Look at L2.
  • N
    Nick
    Nick
    Should CLDX PR the 210th pfs event in the Metric Trial?

    I say yes good info to know when it happens.

    others?
  • N
    Nineteen84
    Nineteen84
    Personally, I'm starting to think, again, that BMS has a standing tentative agreement in place to either infuse Co. with major partnership funds or buy them outright. Who needs CMO if BO is tentative? According to that Cantor note below Co. isn't even looking to replace...hmm..?!
  • R
    Robert
    Robert
    Cantor put a $9 Price Target on this. Research report came out Tuesday. Highlights:

    CLDX's Chief Medical Officer (CMO) Thomas Davis, M.D., is leaving the
    company to take on a role at an early-stage biotechnology company, effective
    9/29/17.
    ■ We do not see implications for CLDX's clinical programs and continue to
    expect data from METRIC (1H18) and varlilumab (2018).
    ■ CLDX will not immediately replace Dr. Davis, but plans to maintain the current
    clinical science team.
    ■ CLDX will be appearing at the Cantor Global Healthcare conference
    September 25-27.
  • R
    Richard
    Richard
    Not sure why the sudden strength in share price. May be good news is coming? No idea, but stocks simply don't make such high percentage move without reason. Waiting to see what happen next.
  • F
    Farnsey
    Farnsey
    Why would a top guy leave during a pivotal time? That's the question.
  • m
    mark
    mark
    Good quality company right here folks. Just look at their past history of many successes. And other posters on this intelligent message board are claiming $40+ by next year. Better start mortgaging all you can for this one.....deal of a lifetime here.
  • m
    martyboy17
    martyboy17
    NTEC + .45 8.95 NEW BUY REC FROM OPPENHEIMER FROM 10 - 15. NAILED IT AT 4.55 ANYONE ELSE GO FOR MY REC RIDE?
  • m
    mark
    mark
    Everyone has got their hopes on Glembas metric trial leading to their first successful drug. Let me tell ya something....companies with a legitimate shot at approval don't trade for $2. The street and all big players know this is a dead end. Marrucci is just playing with the vulnerable small guy now baiting them to keep funding his retirement....actually he has been retired for 20 years.
  • H
    HawkeyeHunter
    HawkeyeHunter
    Wedge on the one month chart. Should be heading higher!
  • m
    mark
    mark
    News Out....Tom Davis has been named as the new CEO of Waste Management. Since he has got an awesome history of taking trash and manipulating it into something someone would buy!!!!!!!!!!!
  • m
    mark
    mark
    When was the last time this co issued any positive information to shareholders? Its pretty evident things are not going good behind closed doors. When Rintega was in its prime they were issuing (false) positive PR's every other day to pump that scam. They arent even trying now....its that bad.
  • F
    FACTSMAN123
    FACTSMAN123
    Market seems to be thinking when AM speaks publicly, it should be factual and important, Lets hope these presumptions are correct since he is speaking on the 26th,
  • A
    Anh
    Anh
    MDGL so sweet today